Stem cell media boosts microneedling benefits
A split-face study investigating facial rejuvenation found better outcomes using microneedling followed by topical application of a stem cell derived conditioned media versus microneedling alone.
Cosmetic procedure complications in darker skin
Some adverse reactions to cosmetic procedures occur more often in patients with darker skin types. Patients should be counseled on appropriate cosmetic procedures for their skin type, according to Cheryl M. Burgess, M.D., at the Skin of Color Update virtual meeting.
My experience with surface radiotherapy
Superficial radiation offers a newer, FDA-approved office-based option that is safe. Steven A. Davis, M.D., shares his experience using surface radiotherapy to treat his patients with non-melanoma skin cancer.
PDL, botulinumtoxinA improves rosacea symptoms
Treatment with a pulsed dye laser followed immediately by intradermal botulinumtoxinA injections appears safe and improved erythema, flushing, burning and pruritus, according to a recent study.
Trial compares NMSC destructive techniques
A recent study showed that curettage and cryotherapy, and electrodesiccation and curettage are two techniques that have comparable cure rates. The study’s findings highlight the efficacy and reliability of these treatment approaches for minimally invasive cutaneous carcinomas.
Phenotype-based approach advances management
The 21-member global ROSacea Consensus panel developed updated recommendations for rosacea, diagnosis, classification and management to support and promote transition to a phenotype approach in rosacea.
Misinformation delays rosacea diagnosis in skin of color patients
The idea that rosacea is uncommon in darker skinned individuals may be due to under-recognition. Careful clinical examination, a thorough history and biopsy in some cases are needed for accurate diagnosis and differentiating rosacea from diseases that may be more common.
The retinoid revolution
Zoe Diana Draelos, M.D., shares why retinoids can be found in many anti-aging formulations and how to reduce irritation from this potent antioxidant.
Managing pandemic patient volumes
Since the start of the pandemic, dermatologists have seen an average 50% drop in patient volume. While teledermatology has offered a channel for non-urgent patients and patient visits are rebounding, overall patient volumes are still significantly lower than 2019.
I warned my patient – was it enough?
In this month’s Legal Eagle article, David J. Goldberg, M.D., J.D., discusses the different professional standards of disclosure that a physician must fulfill when treating patients.
Dupilumab outlasts cyclosporine
Adults with atopic dermatitis (AD) stay on dupilumab (Dupixent, Sanofi and Regeneron) significantly longer than on cyclosporine, according to a recent study.
Lebrikizumab rapidly improves quality of life
Across all doses, lebrikizumab showed significant dose-dependent improvement in primary study endpoints for improvements in atopic dermatitis, according to data from phase 2b trials.
Case series draws attention to phenotype of acne scarring
A retrospective review of patients seen in an academic dermatology clinic over a one-year period identified 20 individuals with nasal papules in association with acne, which are thought to represent scarring sequelae. The condition is underrecognized, researchers say and requires further research to better understand.
Study finds HS associated with acne conglobata
Hidradenitis suppurativa has come to be associated with systemic inflammation as well as a growing list of comorbidities including acne conglobate.
‘Clean’ skincare a growing trend
"Clean" skincare has become a popular trend. A preference for products without certain ingredients is fine if the products make patients feel better without making their skin worse, one expert says.
Drug vehicles deliver benefits
Vehicles for topical atopic dermatitis treatments deliver benefits that promote barrier restoration and enhance innate immune defenses, a review suggests.
Long-term data support tildrakizumab safety, user-friendliness
Phase 3 data show tildrakizumab’s (Ilumya, Sun Pharma) efficacy and safety last up to five years.
Meta-analysis reaffirms safety, efficacy of intermittent biologic use
According to a recent meta-analysis, patients who stop and restart biologic treatment can regain psoriasis control without experiencing unexpected safety issues.
Tape strips detect eczema, psoriasis biomarkers
Tape strips outperformed skin biopsies by differentiating eczema from psoriasis with high accuracy, researchers report.
Therapeutic, management considerations with biologics
Studies offer further insight into risks associated with biologic therapy. One study suggests it’s not necessary to stop biologic therapy preoperatively to limit post-operative infections. Another systematic review does not rule out melanoma risk.
Investigational agents to treat hematologic malignancy in pipeline
Blastic plasmacytoid dendritic neoplasm (BPDCN) is a rare but aggressive hematologic malignancy that often manifests with asymptomatic skin lesions that often appear as bruise-like lesions, plaques or nodules. With one approved drug available, researchers are studying additional investigational agents.
2 Clarke Drive Cranbury, NJ 08512